Vitamin D, acute respiratory infections, and Covid-19: The curse of small-size randomised trials. A critical review with meta-analysis of randomised trials
PLOS ONE · 2025
DOI: 10.1371/journal.pone.0303316 ↗Kurz gefasst
Metaanalyse in der Zeitschrift PLOS ONE, 2025. Verfasst von Philippe Autier und 5 weiteren Autor:innen. Beteiligte Einrichtung: International Prevention Research Institute (iPRI), Bat. L'Américain, Dardilly, France. Hauptthemen laut MEDLINE: Vitamin D, COVID-19, Respiratory Tract Infections. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 71 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Randomised trials conducted from 2006 to 2021 indicated that vitamin D supplementation (VDS) was able to prevent severe COVID-19 and acute respiratory infections (ARI). However, larger randomised trials published in 2022 did not confirm the health benefits of VDS in COVID-19 patients.
Objective
To examine through a systematic review with meta-analysis the characteristics of randomised trials on VDS to COVID-19 patients and admission to intensive care unit (ICU), and of randomised trials on VDS for the prevention of ARI.
Method
A systematic search retrieved randomised trials on VDS to COVID-19 patients and admission to ICU. Data on VDS and ARI were extracted from the meta-analysis of Jolliffe et al. 2021. Groups were formed including trials with total numbers of patients below or above the median size of all trials. The associations between VDS vs no VDS, and admission to ICU were evaluated using random-effects models from which summary odds ratios (SOR) and 95% confidence intervals (CI) were obtained. Meta-analyses were done for all trials and for each group of trials, which allowed testing a possible effect modification of trial size. Publication bias was assessed using the Louis-Furuya-Kanaruori (LFK) index (no bias if index between -1 and +1) and the trim and fill method.
Results
Nine trials on VDS for preventing admission to ICU were identified, including 50 to 548 patients. The summary odds ratio (SOR) was 0.61 (95% CI: 0.39–0.95) for all trials, 0.34 (0.13–0.93) for trials including 50 to
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- International Prevention Research Institute (iPRI), Bat. L'Américain, Dardilly, France.
- Department of Experimental Oncology, European Institute of Oncology, IRCCS, Milano, Italy.
- Academic Centre for General Practice, Department of Public Health and Primary Care, Catholic University Leuven, Leuven, Belgium.
- Belgian Centre for Evidence-Based Medicine, Cochrane Belgium, Leuven, Belgium.
- DG H&WB, Queen Elisabeth Barracks, Belgian Defence, Evere, Belgium.
ORCID-Profile: Philippe Autier, Patrick Vankrunkelsven, Sara Gandini
Zitieren
APA
Autier, P., Doi, G., Mullie, P., Vankrunkelsven, P., D'Ecclesiis, O., & Gandini, S. (2025). Vitamin D, acute respiratory infections, and Covid-19: The curse of small-size randomised trials. A critical review with meta-analysis of randomised trials. PLOS ONE. https://doi.org/10.1371/journal.pone.0303316
Vancouver
Autier P, Doi G, Mullie P, Vankrunkelsven P, D'Ecclesiis O, Gandini S. Vitamin D, acute respiratory infections, and Covid-19: The curse of small-size randomised trials. A critical review with meta-analysis of randomised trials. PLOS ONE. 2025. doi:10.1371/journal.pone.0303316
BibTeX
@article{Autier2025,
author = {Autier, Philippe and Doi, Giulia and Mullie, Patrick and Vankrunkelsven, Patrick and D'Ecclesiis, Oriana and Gandini, Sara},
title = {Vitamin D, acute respiratory infections, and Covid-19: The curse of small-size randomised trials. A critical review with meta-analysis of randomised trials},
journal = {PLOS ONE},
year = {2025},
doi = {10.1371/journal.pone.0303316}
}
EUVIMED